Amneal Pharmaceuticals(AMRX) - 2024 Q4 - Annual Results

Financial Performance - Q4 2024 net revenue was $731 million, an 18% increase from$ 617 million in Q4 2023[3] - Full year 2024 net revenue reached $2.79 billion, a 17% increase compared to$ 2.39 billion in 2023[3] - Q4 2024 adjusted net income was $40 million, with adjusted EBITDA of$ 155 million, reflecting a 9% increase from the previous year[3] - Full year 2024 adjusted EBITDA was $627 million, a 12% increase from the prior year[3] - Adjusted diluted EPS for full year 2024 was$ 0.58, a 9% decrease from $0.64 in 2023[3] - The company provided 2025 financial guidance of$ 3.0 to $3.1 billion in net revenue and$ 650 to $675 million in adjusted EBITDA[4] Segment Performance - Affordable Medicines segment revenue grew by 21% in Q4 2024, driven by new product launches and biosimilars[3] - AvKARE segment revenue increased by 14% in Q4 2024 due to new product launches[3] - Specialty segment revenue grew by 16% in Q4 2024, supported by key branded products including CREXONT®[3] - The Specialty Segment reported net revenue of$ 445,749 for the year ended December 31, 2024, up from $390,457 in 2023, marking a 14.2% increase[47] - The AvKARE Segment achieved net revenue of$ 662,945 for the year ended December 31, 2024, compared to $531,749 in 2023, representing a 24.7% growth[54] Expenses and Losses - Research and development expenses increased to$ 190.7 million for the year ended December 31, 2024, compared to $164.0 million in 2023, reflecting a 16.3% rise[17] - The net loss attributable to Amneal Pharmaceuticals, Inc. for the year ended December 31, 2024, was$ 116.9 million, compared to a net loss of $84.0 million in 2023, representing a 38.9% increase in losses[17] - The company incurred stock-based compensation expenses of$ 7,209 thousand for the three months ended December 31, 2024, compared to $5,974 thousand in the same period of 2023[30] - The company recorded a significant reduction in legal-related charges, with net charges of$ 96,692 in 2024 compared to $10,000 in 2023[40] Assets and Liabilities - Total current assets increased to$ 1,587.8 million as of December 31, 2024, from $1,377.9 million in 2023, marking a 15.2% growth[19] - Total liabilities decreased to$ 3,501.4 million as of December 31, 2024, from $3,472.6 million in 2023, indicating a slight reduction in overall liabilities[19] - Cash and cash equivalents at the end of the period increased to$ 110.6 million in 2024, up from $91.5 million in 2023, a growth of 20.5%[21] Cash Flow and Operating Activities - The company reported a net cash provided by operating activities of$ 295.1 million for the year ended December 31, 2024, compared to $345.6 million in 2023, a decrease of 14.6%[21] Corporate Structure and Strategy - The company implemented a reorganization plan on November 7, 2023, converting to a more traditional C-corporation structure[17] - The company plans to continue focusing on expanding its product pipeline and enhancing operational efficiencies in the upcoming fiscal year[17] - The company plans to continue focusing on market expansion and new product development to drive future growth[41] Leverage and Debt - The company reduced net leverage to 3.9x, ahead of its commitment to be below 4x[2] - The net leverage ratio improved to 3.9x as of December 31, 2024, down from 4.8x as of December 31, 2023[26] - Total gross debt as of December 31, 2024, was$ 2,584,835 thousand, a decrease from $2,766,826 thousand as of December 31, 2023[26]